drugset / Trial / NCT00096538
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Completed
6 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collabNew York Presbyterian Hospital · collabUniversity of North Carolina, Chapel Hill · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma. PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma.
Timeline
- Start
- 2004-04
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valganciclovir | Small molecule | — | Oral |